UNICREDIT BANK/CALL/VERTEX PHARMACEUTICALS/600/0.1/19.03.25 | Real-time Bid/Ask 02:56:13 2024-06-05 EDT | ||
| 1.41 EUR / 1.7 EUR | +0.97% |
|
| Current month | +46.67% | ||
| 1 month | +234.78% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24-06-04 | 1.54 | +15.79% |
| 24-06-03 | 1.33 | +26.67% |
| 24-05-31 | 1.05 | +16.67% |
| 24-05-30 | 0.9 | +4.65% |
| 24-05-29 | 0.86 | -16.50% |
Delayed Quote Börse Stuttgart
Last update June 04, 2024 at 02:44 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
UniCredit
|
| WKN | HD441Z |
| ISIN | DE000HD441Z2 |
| Date issued | 2024-03-25 |
| Strike | 600 $ |
| Maturity | 2025-03-19 (288 Days) |
| Parity | 10 : 1 |
| Emission price | 0.88 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.54 € |
|---|---|
| Lowest since issue | 0.32 € |
| Spread | 0.21 € |
| Spread % | 14.38% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
475
USD
Average target price
463.5
USD
Spread / Average Target
-2.41%
- Stock Market
- Warrants
- Warrant
